Currently Viewing:

Ribociclib Approved as Front-Line Therapy for HR+/HER2- Breast Cancer

Laura Joszt
The FDA has approved Novartisí ribociclib (Kisqali) for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!